About Dova Pharmaceuticals
Dova Pharmaceuticals is a company based in Durham (United States) founded in 2016 was acquired by Swedish Orphan Biovitrum in September 2019. Dova Pharmaceuticals has raised $10 million across 2 funding rounds from investors including Swedish Orphan Biovitrum and Perceptive Advisors. Dova Pharmaceuticals operates in a competitive market with competitors including Editas Medicine, GBT, LogicBio, Kedrion and Modus Therapeutics, among others.
- Headquarter Durham, United States
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$10 M (USD)
in 2 rounds
-
Latest Funding Round
Not available
-
Investors
Swedish Orphan Biovitrum
& 1 more
-
Employee Count
Not available
-
Acquired by
Swedish Orphan Biovitrum
(Sep 30, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Dova Pharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of Dova Pharmaceuticals
Dova Pharmaceuticals has successfully raised a total of $10M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Dova Pharmaceuticals
Dova Pharmaceuticals has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Swedish Orphan Biovitrum and Perceptive Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Developer of therapies for rare diseases like Haemophilia, Inflammation, and Genetic diseases
|
Locked | Locked | Locked |
Investor details for Dova Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Dova Pharmaceuticals
Investment portfolio details for Dova Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Dova Pharmaceuticals
Detailed financials for Dova Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dova Pharmaceuticals Comparisons
Peer comparison for Dova Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Dova Pharmaceuticals
Dova Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Editas Medicine, GBT, LogicBio, Kedrion and Modus Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed using CRISPR technology.
|
|
| Locked | Locked | Locked |
Small molecules are developed for sickle cell disease treatment.
|
|
| Locked | Locked | Locked |
Viral vectors are developed for genetic and infectious disease treatments.
|
|
| Locked | Locked | Locked |
Plasma-derived therapies are developed for hemophilia and immune deficiencies.
|
|
| Locked | Locked | Locked |
Polysaccharide-based drug for Sickle Cell Disease treatment is developed.
|
|
| Locked | Locked | Locked |
Therapies for sickle cell disease and diabetic nephropathy are developed.
|
Detailed competitors of Dova Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dova Pharmaceuticals
Complete news archive for Dova Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dova Pharmaceuticals
Dova Pharmaceuticals was founded in 2016.
Dova Pharmaceuticals is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Dova Pharmaceuticals is a funded company, having raised a total of $10M across 2 funding rounds to date.
Dova Pharmaceuticals was founded in 2016 and is headquartered in Durham, United States. Operations focus on the pharmaceutical sector, specifically the acquisition, development, and commercialization of therapies for rare diseases. The lead product candidate, avatrombopag, an oral thrombopoietin receptor agonist, has completed Phase 3 trials for thrombocytopenia associated with chronic liver disease. An NDA filing is planned for the third quarter of 2017, with further indications under exploration.
Dova Pharmaceuticals's top competitors include GBT, Editas Medicine and Kedrion.
Dova Pharmaceuticals has 2 investors. Key investors include Swedish Orphan Biovitrum, and Perceptive Advisors.